DEXCOM INC

NASDAQ: DXCM (DexCom, Inc.)

最近更新时间: 28 Nov, 12:05PM

63.47

0.94 (1.50%)

  • 1天 1.50%
  • 5天 0.00%
  • 1月 15.40%
  • 6月 -25.92%
  • 今年至今天 -19.15%
  • 1年 -19.05%
  • 5年 -24.75%
前收盘价格 62.53
收盘价格 62.57
成交量 2,241,246
平均成交量 (3个月) 6,460,861
市值 24,890,095,616
市盈率 (P/E TTM) 35.26
预期市盈率 (P/E Forward) 25.84
价格/销量 (P/S) 5.85
股市价格/股市净资产 (P/B) 9.28
52周波幅
54.11 (-14%) — 93.25 (46%)
利润日期 30 Oct 2025
营业毛利率 12.90%
营业利益率 (TTM) 12.91%
稀释每股收益 (EPS TTM) 1.33
季度收入增长率 (YOY) 12.50%
季度盈利增长率 (YOY) -28.00%
总债务/股东权益 (D/E MRQ) 113.97%
流动比率 (MRQ) 1.50
营业现金流 (OCF TTM) 964.10 M
杠杆自由现金流 (LFCF TTM) 509.04 M
资产报酬率 (ROA TTM) 5.97%
股东权益报酬率 (ROE TTM) 23.72%

市场趋势

短期 中期
行业 Medical Devices (US) 混合的 混合的
Medical Devices (全球的) 混合的 混合的
股票 DexCom, Inc. 看跌 看跌

AIStockmoo 评分

1.6
分析师共识 2.0
内部交易活动 NA
价格波动 1.5
技术平均移动指标 1.0
技术振荡指标 2.0
平均 1.63

相关股票

股票 市值 DY P/E（TTM） P/B
DXCM 25 B - 35.26 9.28
PODD 22 B - 97.43 15.63
SSII 1 B - - 30.33
IRTC 6 B - - 48.07
TMDX 4 B - 51.55 14.05
ESTA 2 B - - 125.60

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
部门 Healthcare
行业 Medical Devices
投资方式 Mid Growth
内部持股比例 0.42%
机构持股比例 97.10%
52周波幅
54.11 (-14%) — 93.25 (46%)
目标价格波幅
68.00 (7%) — 99.00 (55%)
高 99.00 (Canaccord Genuity, 55.98%) 购买
中 85.00 (33.92%)
低 68.00 (Evercore ISI Group, 7.14%) 保留
平均值 83.82 (32.06%)
总计 14 购买, 3 保留
平均价格@调整类型 60.65
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 02 Dec 2025 75.00 (18.17%) 购买 64.45
10 Nov 2025 63.00 (-0.74%) 保留 54.84
Evercore ISI Group 25 Nov 2025 68.00 (7.14%) 保留 61.69
Argus Research 07 Nov 2025 90.00 (41.80%) 购买 55.00
Barclays 03 Nov 2025 80.00 (26.04%) 保留 60.43
Truist Securities 03 Nov 2025 82.00 (29.19%) 购买 60.43
15 Oct 2025 94.00 (48.10%) 购买 65.41
UBS 03 Nov 2025 95.00 (49.68%) 购买 60.43
BTIG 31 Oct 2025 85.00 (33.92%) 购买 58.22
Canaccord Genuity 31 Oct 2025 99.00 (55.98%) 购买 58.22
29 Sep 2025 106.00 (67.01%) 购买 66.46
Citigroup 31 Oct 2025 75.00 (18.17%) 购买 58.22
07 Oct 2025 85.00 (33.92%) 购买 66.03
JP Morgan 31 Oct 2025 75.00 (18.17%) 保留 58.22
Piper Sandler 31 Oct 2025 75.00 (18.17%) 购买 58.22
RBC Capital 31 Oct 2025 85.00 (33.92%) 购买 58.22
TD Cowen 31 Oct 2025 84.00 (32.35%) 购买 58.22
Wells Fargo 31 Oct 2025 93.00 (46.53%) 购买 58.22
Stifel 21 Oct 2025 85.00 (33.92%) 购买 69.75
Goldman Sachs 01 Oct 2025 89.00 (40.22%) 购买 66.08
Baird 26 Sep 2025 90.00 (41.80%) 购买 67.10
显示更多

该时间范围内无数据。

  • 3M
日期 类型 细节
05 Dec 2025 公告 Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
05 Dec 2025 公告 SueWallSt Podcast Series Launches With Focus on DexCom, Inc. (DXCM) Fraud Allegations
04 Dec 2025 公告 Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
04 Dec 2025 公告 Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
04 Dec 2025 公告 DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Dec 2025 公告 Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
02 Dec 2025 公告 DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
02 Dec 2025 公告 Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
01 Dec 2025 公告 DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
01 Dec 2025 公告 Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
25 Nov 2025 公告 GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
25 Nov 2025 公告 DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Nov 2025 公告 DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
20 Nov 2025 公告 Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
20 Nov 2025 公告 DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
19 Nov 2025 公告 Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
18 Nov 2025 公告 Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
18 Nov 2025 公告 DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
17 Nov 2025 公告 Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
14 Nov 2025 公告 Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
06 Nov 2025 公告 Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
06 Nov 2025 公告 Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
30 Oct 2025 公告 Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
27 Oct 2025 公告 Dexcom Appoints Euan Ashley to Board of Directors
02 Oct 2025 公告 Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
15 Sep 2025 公告 Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
10 Sep 2025 公告 Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票